What type of study is this?

This is a In Vitro Study study (also classified as: Pre-Registered Trial).

December 8, 2025BloodOpen Access

A phase 1/1b open-label, dose escalation, first-in-human study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-leukemic activity of the orally available clk inhibitor, BH-30236, in adults with R/R AML or HR-MDS

View Full Paper

Ask AI

Bookmark

BH-30236 significantly improved apoptosis in AML cells, enhancing cancer cell death.
In vitro studies showed BH-30236's combination with venetoclax has superior efficacy over standard treatments.
This trial evaluates safety and pharmacokinetics of BH-30236 in a phase 1/1b design across multiple sites.
These findings indicate new therapeutic strategies may be possible for AML with resistance to current therapies.

No takes yet. Share an insight, caveat, or question.

Phase 1 trial shows improved apoptosis in AML patients, suggesting BH-30236 may enhance effects of venetoclax.

Xie et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark